- Company
- Tabrecta/ Rybrevant are expected to enter the market
- by Eo, Yun-Ho Oct 13, 2021 05:47am
- Two types of anticancer drugs targeting MET gene mutations are expected to enter the domestic market. According to related industries, Novartis Korea and Janssen Korea submitted applications to the MFDS for approval of the new anticancer drugs Tabrecta (Capmatinib) and Rybrevant (Amivantamab), respectively, and are currently undergoing screen
- Company
- ‘Rinvoq’ tries AD reimbursement following ‘Olumiant’
- by Eo, Yun-Ho Oct 12, 2021 05:50am
- Companies have been actively seeking insurance benefits for their JAK inhibitors in atopic dermatitis. According to industry sources, Abbvie Korea has also applied for the reimbursement of its ‘Rinvoq (upadacitinib)’ in atopic dermatitis after its indication expansion, following Lilly Korea’s reimbursement application for ‘Olumiant (b
- Company
- SK Bioscience will also produce COVID-19 vaccines next year
- by Chon, Seung-Hyun Oct 12, 2021 05:49am
- SK Bioscience will also entrust production of COVID-19 vaccines from global pharmaceutical companies next year. SK Bioscience announced on the 5th that it has signed an extension contract for the use of Andong L House facilities with CEPI in Brussels, Belgium. It will extend the period of using some of the undiluted production facilities in
- Company
- Dupixent reimbursement in pediatric AD is being discussed
- by Eo, Yun-Ho Oct 8, 2021 05:57am
- Discussion on prescribing ‘Dupixent’ to pediatric patients with atopic dermatitis is now showing visible progress. According to industry sources, the National Health Insurance Service has started expert inquiries to start discussions on applying insurance benefits to the lower-dose (200mg) formulation of Sanofi-Aventis Korea’s Dupixent
- Company
- PARP inhibitor Zejula, which is partially covered
- by Oct 8, 2021 05:57am
- PARP inhibitor Zejula could be reimbursed as the primary maintenance therapy for ovarian cancer. However, it is pointed out that "regulatory agencies should change their perspectives" due to benefit standards. Kim Jaewon, professor of obstetrics and gynecology at Seoul National University Hospital, is taking Korea on the 7th. At the Zejula on
- Company
- Lynparza was approved for pancreatic cancer/ prostate cancer
- by Oct 8, 2021 05:56am
- PARP inhibitor "Lynparza (Olaparib)" has expanded its indications to pancreatic and prostate cancer. AstraZeneca Korea announced on the 7th that it has been approved by the MFDS for Lynparza's indications for pancreatic and prostate cancer. As a result, Lynparza can be used for ▲ maintenance therapy in adult patients with gBRCA mutated pa
- Company
- Latecomer JAKi ‘Rinvoq’ now has the most indications
- by Oct 8, 2021 05:56am
- The latecomer JAK inhibitor, Abbvie’s ‘Rinvoq,’ is seeking to overturn the market landscape by greatly expanding its indications. Whether the drug can break the two-way lead battle between Xeljanz and Olumiant, is gaining attention. According to the Ministry of Food and Drug Safety, Abbvie’s ‘Rinvoq (upadacitinib)’ received addition
- Company
- Roche and Lilly to launch RET targeted cancer drugs in Korea
- by Eo, Yun-Ho Oct 6, 2021 06:06am
- Two types of RET targeted anticancer therapies are concurrently seeking domestic entry. According to industry sources, Roche Korea's Gavreto (pralsetinib)’ and Lilly Korea ‘Retevmo (selpercatinib)’ are under review for domestic approval. Both are anticancer drugs that target RET (Rearranged during transfection) gene fusions. The d
- Company
- Evrysdi (PO) is differentiated due to its low price
- by Oct 6, 2021 06:06am
- Roche's "Evrysdi (Risdiplam)," the second treatment for spinal muscular atrophy (SMA) in Korea, signaled its launch after about a year of approval. With the differentiation of the only PO drug and low prices, fierce competition in the SMA market was predicted. "Evrysdi is the first oral drug among SMA treatments and is applicable to patien
- Company
- Yoo Byung-Jae took office as the new president of Novartis
- by Oct 6, 2021 06:05am
- Yoo Byung-Jae took office on the 1st as the new president of Novartis Korea. New President Yoo is an expert who has accumulated organizational management and management skills in the global healthcare industry for 15 years. Until recently, he served as president of North Asia, including South Korea, Taiwan, and Hong Kong, at Johnson & Joh
